The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

“This study represents a major step forward in how we respond to cardiac arrest in the United States,” explained Monique Starks, MD, principal investigator. “By integrating drone technology into emergency care, we’re working to close the critical gap between cardiac arrest and treatment."

The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.

About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.

The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.

Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes. 

Procizumab was developed to change the trajectory of shock by addressing an underlying molecular driver rather than just managing symptoms.